Article
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
International journal of molecular sciences - 4 Dec 2023
Scaglione Giovanni L, Pignata Sandro, Pettinato Angela, Paolillo Carmela, Califano Daniela, Scandurra Giuseppa, Lombardo Valentina, Di Gaudio Francesca, Pecorino Basilio, Mereu Liliana, Scollo Paolo, Capoluongo Ettore D
Abstract excerpt
High-grade serous ovarian cancer (HGSOC) patients carrying the BRCA1/2 mutation or deficient in the homologous recombination repair system (HRD) generally benefit from treatment with PARP inhibitors. Some international recommendations suggest that BRCA1/2 genetic testing should be offered for all newly diagnosed epithelial ovarian cancer, along with HRD assessment. Academic tests (ATs) are continuously under...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.